Clinical features and outcome of vertebral osteomyelitis after spinal injection: is it worth the price?
Comorbidity
Psoas abscess
Spinal injection
Staphylococcus aureus
Survival
Vertebral osteomyelitis
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
31
01
2023
accepted:
14
03
2023
medline:
25
5
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
ppublish
Résumé
Spinal injections are increasingly used for back pain treatment. Vertebral osteomyelitis (VO) after spinal injection (SIVO) is rare, but patient characteristics and outcome have not been well characterized. The aim of this study was to assess patient characteristics of SIVO in comparison to patients with native vertebral osteomyelitis (NVO) and to determine predictors for 1-year survival. This is a single-center cohort study from a tertiary referral hospital. This is a retrospective analysis of Patients with VO who were prospectively enrolled into a spine registry from 2008 to 2019. Student's t-test, Kruskal-Wallis test or Chi-square test were applied for group comparisons. Survival analysis was performed using a log-rank test and a multivariable Cox regression model. 283 VO patients were enrolled in the study, of whom 44 (15.5%) had SIVO and 239 (84.5%) NVO. Patients with SIVO were significantly younger, had a lower Charlson comorbidity index and a shorter hospital stay compared to NVO. They also showed a higher rate of psoas abscesses and spinal empyema (38.6% [SIVO] vs. 20.9% [NVO]). Staphylococcus aureus (27%) and coagulase-negative staphylococci (CNS) (25%) were equally often detected in SIVO while S. aureus was more frequently than CNS in NVO (38.1% vs. 7.9%).Patients with SIVO (P = 0.04) had a higher 1-year survival rate (Fig. 1). After multivariate analysis, ASA score was associated with a lower 1-year survival in VO. The results from this study emphasize unique clinical features of SIVO, which warrant that SIVO should be estimated as a separate entity of VO.
Identifiants
pubmed: 37071309
doi: 10.1007/s15010-023-02024-9
pii: 10.1007/s15010-023-02024-9
pmc: PMC10205873
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
599-607Informations de copyright
© 2023. The Author(s).
Références
Spine (Phila Pa 1976). 2020 Oct 15;45(20):1426-1434
pubmed: 32453235
J Hosp Infect. 2021 Oct;116:1-9
pubmed: 34298033
Eur Radiol. 2018 Jan;28(1):418-427
pubmed: 28726118
Cureus. 2020 Aug 4;12(8):e9559
pubmed: 32905554
Pain Physician. 2016 Mar;19(3):E365-410
pubmed: 27008296
Spine J. 2019 May;19(5):880-887
pubmed: 30500465
Ann Intern Med. 2015 Sep 1;163(5):373-81
pubmed: 26302454
N Engl J Med. 2022 May 5;386(18):1732-1740
pubmed: 35507483
Pain Physician. 2008 Sep-Oct;11(5):693-7
pubmed: 18850035
Korean J Anesthesiol. 2017 Feb;70(1):90-94
pubmed: 28184274
J Clin Microbiol. 2000 Aug;38(8):2819-23
pubmed: 10921933
Infection. 2018 Oct;46(5):679-686
pubmed: 30003490
Arch Intern Med. 2012 Jan 23;172(2):134-42
pubmed: 22157067
Acta Neurochir (Wien). 2018 Mar;160(3):487-496
pubmed: 29356895
Spine (Phila Pa 1976). 2003 Jun 1;28(11):E209-11
pubmed: 12782996
Clin Microbiol Infect. 2015 Mar;21(3):254.e1-8
pubmed: 25618436
N Engl J Med. 2014 Jul 3;371(1):11-21
pubmed: 24988555
Spine J. 2015 Jun 1;15(6):1233-40
pubmed: 25701609
Eur J Clin Microbiol Infect Dis. 2020 Nov;39(11):2065-2076
pubmed: 32591898
Curr Rev Musculoskelet Med. 2008 Dec;1(3-4):212-22
pubmed: 19468908
Clin Infect Dis. 2015 Sep 15;61(6):859-63
pubmed: 26316526
Open Forum Infect Dis. 2020 May 20;7(6):ofaa176
pubmed: 32523973
J Chemother. 2020 Dec;32(8):411-419
pubmed: 32372690
South Med J. 2014 Aug;107(8):528-9
pubmed: 25084194
N Engl J Med. 2013 Oct 24;369(17):1598-609
pubmed: 23252499
Paraplegia. 1969 Nov;7(3):179-92
pubmed: 5360915
Anesthesiology. 2021 Nov 1;135(5):904-919
pubmed: 34491303
Clin Microbiol Infect. 2014 Oct;20(10):1055-60
pubmed: 24766063